LumipulseĀ® pTau-217/Beta Amyloid 42 Ratio now available nationwide through Labcorp BURLINGTON, N.C., Aug. 18, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the LumipulseĀ® pTau-217/Beta...
Related Questions
How will the launch of the FDAācleared blood test affect Labcorpās revenue forecasts and earnings guidance?
Will this new test give Labcorp a competitive edge over rivals in the neurology diagnostics market and how might it impact its market share?
What is the expected adoption rate for the Lumipulse pTauā217/Beta Amyloid 42 Ratio test versus existing Alzheimerās diagnostics?